Pharma News

Breast cancer survivors are especially vulnerable to dyspareunia, or painful sexual intercourse, because their treatment mainly focuses on eradicating the sex hormone estrogen. A new research has suggested that application of liquid lidocaine, a common local anesthetic, may significantly improve sexual function of breast cancer survivors who experience pain during sexual intercourse. The research appeared online in the Journal of Clinical Oncology.

Medical researchers have claimed that men who experience erectile dysfunction might face twice the risk of Type 2 Diabetes compared to men without such sexual incapability. The story is published in Annals of Family Medicine.

New research, published in The Leadership Quarterly, highlights the influence of power in leader corruption. When appointing a new leader, selectors base their choice on several factors and typically look for leaders with desirable characteristics such as honesty and trustworthiness. However once leaders are in power, can we trust them to exercise it in a prosocial manner?

Arsenic, which can be present in ground water, modifies an enzyme that alters the secretion of insulin in the pancreas. Physicians, usually, show type II diabetes as a consequence of an exaggerated food intake and lack of exercise.

[adsense:336x280:8701650588]

Unichem Pharmaceuticals (USA) is a wholly-owned subsidiary of the company, is voluntarily recalling one lot of Hydrochlorothiazide Tablets 25 mg 1000-count bottle at the consumer level, US Food and Drug Administration (USFDA) said in a statement.

Vodafone Business Services (VBS) collaborate with Diabetacare to launch dCare Smart, a device that helps people manage diabetes better. The device transmits blood sugar results to a secure Diabetacare server, where they are constantly monitored by diabetes specialist clinicians at the Diabetacare’s Diabetes Management Centre (DMC). dCare Smart is paired with the back-end clinical servers which connect directly to the electronic medical record system, wherein access is given to patients and their caregivers to keep them informed and better manage the condition.

Which plays a crucial role in malaria infection, and may lead to potential new drug to fight the disease. The study is published in Journal of Experimental Medicine.

Biocon’s novel drug pipeline which has an ophthalmology molecule, QPI-1007, is entering clinical trial phase. QPI-1007 is for ocular neuroprotection in NAION and acute angle closure glaucoma. In mid-December 2013, the company entered into a licensing and collaboration agreement for the development of a range of siRNA (small interfering RNA) based novel therapeutics with Quark Pharmaceuticals which was researching on QPI-1007.